Projects per year
Personal profile
Biography
Dr Gareth Gregory is Director of the Haematology Clinical Research Unit and leads the aggressive lymphoma service at Monash Health and School of Clinical Sciences at Monash Health, Monash University. He is a Senior Research Fellow at Monash University and Victorian Cancer Agency Clinical Research Fellow. Dr Gregory is an alumnus of the European Haematology Association Clinical Research Training in Haematology Fellowship and past recipient of the prestigious Albert Baikie Memorial Medal from the Haematology Society of Australia and New Zealand for his research into new treatments for aggressive lymphoma.
Dr Gregory’s main passion in Haematology is to improve outcomes for patients with lymphoma through access to clinical trials and translational research to better select therapies for patients. He is a member of the Australasian Leukaemia & Lymphoma Group working parties for lymphoma and for laboratory science, is a founding Steering Committee member for the Australasian Lymphoma Alliance, and is a member of the Women in Lymphoma Champions of Change committee. He is very active in national and international clinical research, including as principal investigator for a number of studies investigating treatments to improve outcomes for patients with lymphoma and other blood disorders. Dr Gregory is dedicated to advocating for research activities across Monash Health and currently sits on the Human Research Ethics Committee and Clinical Trials Centre Strategy and Governance committee.
Dr Gregory supervises higher degree research students at Monash University across the spectrum of clinical, translational and registry blood cancer research.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Cancer Therapeutics, Doctor of Philosophy, Targeting cyclin-dependent kinase 9 and myeloid cell leukaemia 1 in MYC-driven B-cell lymphoma, University of Melbourne
Award Date: 27 May 2017
External positions
Clinical & Laboratory Haematologist, Monash Health
2013 → …
Collaborations and top research areas from the last five years
-
A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO-501A, AN ANTI-CD19 ALLOGENEIC CAR T CELL THERAPY, AND ALLO-647, AN ANTI-CD52 MONOCLONAL ANTIBODY, IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)
21/09/23 → 20/09/28
Project: Research
-
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study
Manos, K., Churilov, L., Grigg, A., Di Ciaccio, P., Wong, J., Chandra Sekaran, U., Wight, J., Goh, Z., Jina, H., Butler, L., Yannakou, C. K., Hamad, N., Gregory, G. P., Gangatharan, S., Cochrane, T., Hawkes, E. A. & Lasica, M., Jul 2024, In: British Journal of Haematology. 205, 1, p. 146-157 12 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
New standards of care for treatment of diffuse large B-cell lymphoma
Abeyakoon, C. & Gregory, G. P., Apr 2024, In: British Journal of Haematology. 204, 4, p. 1132-1134 3 p.Research output: Contribution to journal › Comment / Debate › Other › peer-review
Open Access -
An open-label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti-PD-1 treatment
Lavie, D., Johnson, N., Borchmann, P., Herrera, A. F., Avigdor, A., Gasiorowski, R., Gregory, G., Keane, C., Vucinic, V., Bazargan, M., Herishanu, Y., Minuk, L., Tzoran, I., Andreadis, C., Armand, P., Kuruvilla, J., Zinzani, P. L., Marceau West, R., Pillai, P., Marinello, P., & 1 others , Jun 2023, In: Hematological Oncology. 41, S2, p. 364-366 3 p., 263.Research output: Contribution to journal › Meeting Abstract › peer-review
Open Access -
A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Cheson, B. D., Assouline, S., Munir, T., Langerbeins, P., Tam, C., Gregory, G. P., Morschhauser, F., Jurczak, W., Choi, M. Y., Shouse, G., Tani, M., Paris, G., Sun, W., Atwal, S. K., Hong, W. J. & Sarkozy, C., 2023, p. 19. 1 p.Research output: Contribution to conference › Poster › peer-review
-
Interim 3-Dimensional volumetric response (3DVR) is associated with better overall survival of patients (pts) with primary central nervous system lymphoma (PCNSL)
Martynchyk, A., O'Shaughnessy, J., Lee, S., Chong, G., Agrawal, S., Tatarczuch, M., Narisa, A. A., Gregory, G. P., Churilov, L. & Hawkes, E. A., Jun 2023, In: Hematological Oncology. 41, S2, p. 349-350 2 p.Research output: Contribution to journal › Meeting Abstract › peer-review
Open Access
Prizes
-
Albert Baikie Memorial Medal for best presentation by a new investigator at the HSANZ Annual Scientific Meeting
Gregory, Gareth (Recipient), 2014
Prize: Prize (including medals and awards)
-
Cancer Therapeutics CRC PhD Top Up Scholarship
Gregory, Gareth (Recipient), 2015
Prize: Competitive Fellowships
-
European Hematology Association Clinical Research Training in Hematology Fellowship
Gregory, Gareth (Recipient), 2017
Prize: Prize (including medals and awards)
-
-
NHMRC Medical Postgraduate Research Scholarship
Gregory, Gareth (Recipient), 2013
Prize: Competitive Fellowships
Activities
-
Lymphoma Australia Conference 2023
Gareth Gregory (Organiser)
21 Jul 2023Activity: Participating in or organising an event types › Contribution to conference
-
Scientific Advisory Committee Member
Gareth Gregory (Fellow)
2023 → …Activity: External Academic Engagement › Professional association or peak discipline body
-
Relapsed/Refractory DLBCL Patient Information Session (Lymphoma Australia)
Gareth Gregory (Contributor)
17 Apr 2023Activity: Community Talks, Presentations, Exhibitions and Events › Public lecture/debate/seminar
-
Cyclin around and around again targeting transcriptional CDKs in lymphoid malignancy
Gareth Gregory (Organiser)
31 May 2023Activity: Participating in or organising an event types › Contribution to workshop, seminar, course
-
Co-Chair, Lymphoma Working Party
Gareth Gregory (Fellow)
2023 → …Activity: External Academic Engagement › Professional association or peak discipline body